Gustafson H, Johansson B, Edsmyr F
Eur Urol. 1981;7(6):346-8. doi: 10.1159/000473262.
22 patients with Peyronie's disease have been treated with Orgotein, the new anti-inflammatory metalloprotein which pronounced superoxide dismutase activity patients with long-standing and severe symptoms were selected for the trial. The drug was given monthly by injection into the indurated areas of penis. In 19 patients, where the sexual act could be performed with difficulties or the penile angulation made intercourse impossible, marked improvement was seen or normal function was restored. No adverse reactions by Orgotein were seen.
22例佩罗尼氏病患者接受了奥古蛋白治疗,奥古蛋白是一种新型抗炎金属蛋白,具有显著的超氧化物歧化酶活性。选取了有长期严重症状的患者进行试验。药物每月注射到阴茎硬结部位。在19例患者中,原本性交困难或阴茎弯曲导致无法性交,治疗后均有显著改善或恢复了正常功能。未观察到奥古蛋白的不良反应。